Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEEP study of high-induction-dose adalimumab in moderate to severe plaque psoriasis
2016-001593-15Phase 3Terminated
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Aug 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis and plaque psoriasis comparing High induction adalimumab with Standard induction adalimumab with placebo masking (2 arms). Primary endpoint: PASI 90 response at week 12. Started Aug 2016; status: terminated.
02
Drugs
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2016-001593-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001593-15.